Global Breast Cancer Treatment Market | Growth | Trends | Analysis 2025

Posted by venkatakiran on October 3rd, 2019

Global Breast Cancer Treatment Market was Valued at US$ XX Mn in 2018, Rising Prevalence of Cancer Rates.

Analyst Speak:

“The Global Breast Cancer Treatment Market was valued around US$ XX Mn by 2018 and growing at a significant CAGR of XX% over next seven years 2019-2025 owing to rising prevalence of cancer rates”

The global breast cancer treatment market accounted for US$ XX Mn in 2018 and burgeoning over the forthcoming years. Some of the key factors boosting the market growth are rising prevalence of cancer rates, technological advancements in cancer biology coupled with introduction of various diagnostic & screening programs, easy availability of treatment of cancer and supportive government initiatives & improvement in the healthcare facilities. However, lack of awareness and huge cost involved in drug development are hampering the growth of the market.

Global breast cancer treatment market segmented on the basis of drug class, distribution channel and region.

Request Sample Report:

https://www.precisionbusinessinsights.com/request-sample?product_id=15801

Taxanes Dominate the Global Breast Cancer Treatment Market

Based on drug class, global breast cancer treatment market segmented into taxanes, hormonal therapy, epothilones, aromatase inhibitors, antimetabolites, anthracyclines, alkylating agents and selective oestrogen-receptor modulators. Taxanes segment held considerable market growth during estimated period. It is a type of drug that blocks cell growth by stopping mitosis (cell division). Taxanes interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A taxane is a type of mitotic inhibitor and a type of antimicrotubule agent. The introduction of taxanes marked a significant advance in the treatment of MBC (metastatic breast cancer). According to the clinical trials, these potent antitumor agents provide improved outcomes for patients with both early and advanced disease and these are among the most active chemotherapy agents used in the management of metastatic breast cancer.